Kato H, Kagami Y, Tachimori Y, Watanabe H, Ikeda H
Department of Surgery, National Cancer Center Hospital, Tokyo, Japan.
J Surg Oncol. 1996 Jul;62(3):214-7. doi: 10.1002/(SICI)1096-9098(199607)62:3<214::AID-JSO12>3.0.CO;2-6.
Twenty-six patients with esophageal carcinoma at stage pT4 underwent esophagectomy with lymph node dissection leaving part of the tumor in adjacent organs. Several plastic catheters were fixed to the tumor bed and led to the outside of the thorax for postoperative brachytherapy. Using these catheters, the patients underwent brachytherapy followed by external beam irradiation. The operative mortality rate was 11.5%. No serious complications resulting directly from the brachytherapy occurred. Recurrent disease was found in 17 patients, among whom only six had local recurrence. The median survival of the patients was 314 days, and the 5-year survival rate was 16.2%. Of the 10 patients at stage pT4N0, three survived more than three years after surgery. Tumor bed implant brachytherapy for residual tumor after esophagectomy is a safe and useful treatment strategy for patients with pT4 tumor, especially those without lymph node metastasis.
26例pT4期食管癌患者接受了食管癌切除术并进行淋巴结清扫,肿瘤部分残留于相邻器官。几根塑料导管固定于瘤床并引至胸外用于术后近距离放疗。利用这些导管,患者接受了近距离放疗,随后进行外照射。手术死亡率为11.5%。未发生直接由近距离放疗导致的严重并发症。17例患者出现疾病复发,其中仅6例为局部复发。患者的中位生存期为314天,5年生存率为16.2%。在10例pT4N0期患者中,3例术后存活超过3年。食管癌切除术后对残留肿瘤进行瘤床植入近距离放疗,对于pT4期肿瘤患者,尤其是无淋巴结转移的患者,是一种安全且有效的治疗策略。